Breaking the Drug Resistance Dilemma of the "King of Cancers": Daraxonrasib Reshapes the Landscape of RAS-Targeted Therapy for Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), with its extreme aggressiveness, concealment, and drug resistance, has long ranked among the deadliest malignancies, widely recognized as the "king of cancers" in clinical and biological industries. Data show that over 90% of advanced pancreatic cancers exhibit abnormal activation of the RAS pathway, with KRAS mutations being the most prevalent. However, for decades, the RAS target has been considered "undruggable" due to its unique structure and concealed binding sites. Traditional chemotherapy and conventional targeted drugs have shown limited efficacy for late-stage patients, with median overall survival in second-line treatment stagnating at around 6 months, creating a clinical treatment bottleneck. In 2026, multiple groundbreaking clinical data emerged, with the breakthrough results of the novel pan-RAS (ON) inhibitor Daraxonrasib (RMC-6236) completely rewriting the landscape of pancreatic cancer targeted therapy, bringing transformative changes to biological targeted drug development and clinical treatment for advanced pancreatic cancer.

Daraxonrasib, developed by Revolution Medicines, is a next-generation oral selective pan-RAS inhibitor. Its core mechanism differs from traditional KRAS G12C inhibitors, which is its key advantage in addressing the challenges of pancreatic cancer treatment. Traditional KRAS inhibitors target only the G12C mutation subtype, limiting their applicability, whereas pancreatic cancer KRAS mutations include G12D, G12V, G12C, and other subtypes, making single-target drugs ineffective for most patients. Daraxonrasib specifically binds to activated RAS mutant proteins, locking the RAS-GTP active conformation and blocking the RAS downstream RAF-MEK-ERK proliferation signaling pathway, fundamentally inhibiting the proliferation, invasion, and metastasis of pancreatic cancer cells. This enables comprehensive targeted suppression of multiple RAS mutation subtypes, perfectly aligning with the genetic mutation profile of pancreatic cancer. Additionally, its oral administration offers convenience, and its optimized small-molecule structure significantly enhances targeting specificity while reducing off-target effects, laying a safety foundation for long-term use.

2026 marked a milestone year for Daraxonrasib in pancreatic cancer indications, with Phase I/II and III clinical trials delivering transformative results, published in *The New England Journal of Medicine* and presented at the ASCO annual meeting, completely redefining the efficacy ceiling for refractory advanced pancreatic cancer. Previously, late-stage pancreatic cancer patients receiving traditional second-line chemotherapy had an objective response rate (ORR) below 10% and a median overall survival (OS) of only around 6 months, with a dismal prognosis. Daraxonrasib achieved a leapfrog breakthrough in clinical data: trials showed an ORR of 29% in previously treated metastatic RAS-mutant pancreatic cancer, with response rates reaching 47% in some cohorts, a 6-month progression-free survival rate of 71%, and a 6-month overall survival rate of 83%, doubling core survival metrics. Pivotal Phase III trial results confirmed that Daraxonrasib extended median overall survival to 15.6 months, more than double that of standard chemotherapy, with rapid onset and durable efficacy, demonstrating highly potent and sustained antitumor activity.

Safety and tolerability are critical for the clinical application of targeted drugs and a core consideration in biological drug development. Current clinical data indicate that Daraxonrasib's safety profile is significantly superior to traditional chemotherapy and other targeted drugs. Adverse reactions are mostly mild to moderate, primarily gastrointestinal effects, mild fatigue, and skin toxicity, with a far lower incidence of grade 3 or higher severe adverse events compared to chemotherapy regimens and no uncontrolled specific toxicities. Unlike traditional chemotherapy, which causes severe myelosuppression, intense vomiting, and liver/kidney damage, Daraxonrasib precisely targets tumor cells, minimizing damage to normal tissues and significantly improving treatment adherence and quality of life for advanced patients. Additionally, its lower resistance rate addresses the industry pain point of rapid efficacy decline in traditional targeted drugs, enabling long-term maintenance therapy for pancreatic cancer. Currently, the drug has received FDA Breakthrough Therapy designation for treating previously treated KRAS-mutant metastatic pancreatic ductal adenocarcinoma, with its approval process accelerating.

From a biological R&D perspective, Daraxonrasib's breakthrough is not just the success of a new drug but a major milestone in RAS target druggability, offering a novel approach for solid tumor targeted therapy. Pancreatic cancer has historically suffered from low targeted drug success rates due to its dense tumor microenvironment, severe stromal fibrosis, and high target heterogeneity, with numerous candidates failing in clinical trials. Daraxonrasib transcends the limitations of single-mutation subtype targeting with its "pan-RAS activated-state inhibition" strategy, overcoming the technical challenges of RAS conformational variability and broad-spectrum inhibition, providing a new paradigm for highly heterogeneous solid tumors. Furthermore, its strong single-agent efficacy and safety profile create ample room for combination therapy development, with ongoing trials exploring its synergy with immune checkpoint inhibitors and anti-angiogenic drugs, potentially further elevating treatment efficacy.

As an innovative drug in late-stage clinical development, Daraxonrasib still faces unresolved industry challenges. First, current clinical data primarily focus on previously treated advanced patients, and its efficacy in first-line treatment and long-term survival benefits require validation in large Phase III trials. Second, some patients still develop secondary resistance, with mechanisms not fully elucidated. Third, the drug's indication is limited to RAS-mutant populations, covering over 90% of pancreatic cancer patients but excluding wild-type cases. Additionally, post-approval accessibility, pricing, and real-world efficacy validation are critical for successful commercialization.

In summary, Daraxonrasib, with its broad-spectrum targeting, breakthrough survival benefits, and manageable safety, has shattered the industry's long-standing dilemma of "no effective targeted drugs" for pancreatic cancer and overturned the entrenched belief that RAS is undruggable. In the era of rapid advancements in precision medicine, this drug not only offers hope for advanced pancreatic cancer patients but also reshapes the technical roadmap for RAS-targeted therapy in solid tumors, providing a critical reference for tackling refractory cancers. As clinical trials progress and commercialization unfolds, Daraxonrasib is poised to become a cornerstone of precision therapy for pancreatic cancer, ushering the field from the "chemotherapy-dominated era" into a "new era of precision targeting."